本文翻译正在准备中。在此之前，我们暂时显示英文原文。
商业 · 2021/6/111 分钟阅读
Determination of Regulatory Review Period for Purposes of Patent Extension; BRAVECTO; Correction
本地自动翻译 · 来源原始语言
摘要
The Food and Drug Administration (FDA or Agency) published a notice in the Federal Register of February 12, 2018. After review of a timely request for reconsideration by the applicant of the determination of the regulatory review period of the animal drug, BRAVECTO, in that notice, FDA has determined that a revision of the SUPPLEMENTARY INFORMATION section is warranted. This document presents the revised regulatory review period.
来源原始语言: Federal Register — Food and Drug Administration打开原始公告 →